Cargando…
1251. Determinants of Infection at a Nontransplanting Cardiothoracic LVAD Program
BACKGROUND: Left ventricular assist devices (LVADs) are a treatment option for end-stage heart failure, traditionally used as a bridge to a transplant. However, LVADs as a destination therapy is an option for individuals with contraindications for transplant. Infections are a common and devastating...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809134/ http://dx.doi.org/10.1093/ofid/ofz360.1114 |
_version_ | 1783461910343057408 |
---|---|
author | Milgrom, Alexander Collins, Amanda Grubbs, J Aaron Derrick, Caroline Logan, Kristin Edelson, William Branham, Stephany Mardis, Andrew Martin, Jeffrey Weissman, Sharon |
author_facet | Milgrom, Alexander Collins, Amanda Grubbs, J Aaron Derrick, Caroline Logan, Kristin Edelson, William Branham, Stephany Mardis, Andrew Martin, Jeffrey Weissman, Sharon |
author_sort | Milgrom, Alexander |
collection | PubMed |
description | BACKGROUND: Left ventricular assist devices (LVADs) are a treatment option for end-stage heart failure, traditionally used as a bridge to a transplant. However, LVADs as a destination therapy is an option for individuals with contraindications for transplant. Infections are a common and devastating complication with significant morbidity and mortality. The purpose of this study was to assess the impact of risk factors for LVAD-associated infections in a nontransplant LVAD center. METHODS: All patients with implanted LVADs from 2013–2018 at Prisma Health were screened for inclusion. LVAD-associated infection was defined using INTERMACS criteria. Patient characteristics and device characteristics were evaluated for infection risk. Time to infection and associated mortality were also analyzed. RESULTS: Fifty-four of 138 (39.1%) patients developed an LVAD infection (driveline infection, or bacteremia). Mean time to infection among those who experienced infections was 7.78 months, with a standard deviation of 9.58 months. Table 1 summarizes baseline patient characteristics. HeartWare devices, compared with HeartMate II, were at an increased risk of infections and had a shorter time to infection (Figure 1) (HeartWare vs. HeartMate II, HR 2.12, P = 0.01). Those with a BMI of ≥35 kg/m(2) were found on average to have a number of infections 0.729 greater than those with a BMI < 35 kg/m(2) (P = 0.01). Prealbumin, A1C, and chronic kidney disease (any stage) were not found to be associated with infection. Staphylococcus aureus (21, 18.26%), Pseudomonas aeruginosa (24, 20.87%), and Staphylococcus epidermidis (22, 19.13%) were the most common organisms identified. CONCLUSION: In an LVAD center where the majority of patients received LVAD as destination therapy, infection rates were similar as those receiving LVAD as a bridge to transplant. Modifiable risk factors for infection are areas for future interventions and prevention efforts. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6809134 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68091342019-10-28 1251. Determinants of Infection at a Nontransplanting Cardiothoracic LVAD Program Milgrom, Alexander Collins, Amanda Grubbs, J Aaron Derrick, Caroline Logan, Kristin Edelson, William Branham, Stephany Mardis, Andrew Martin, Jeffrey Weissman, Sharon Open Forum Infect Dis Abstracts BACKGROUND: Left ventricular assist devices (LVADs) are a treatment option for end-stage heart failure, traditionally used as a bridge to a transplant. However, LVADs as a destination therapy is an option for individuals with contraindications for transplant. Infections are a common and devastating complication with significant morbidity and mortality. The purpose of this study was to assess the impact of risk factors for LVAD-associated infections in a nontransplant LVAD center. METHODS: All patients with implanted LVADs from 2013–2018 at Prisma Health were screened for inclusion. LVAD-associated infection was defined using INTERMACS criteria. Patient characteristics and device characteristics were evaluated for infection risk. Time to infection and associated mortality were also analyzed. RESULTS: Fifty-four of 138 (39.1%) patients developed an LVAD infection (driveline infection, or bacteremia). Mean time to infection among those who experienced infections was 7.78 months, with a standard deviation of 9.58 months. Table 1 summarizes baseline patient characteristics. HeartWare devices, compared with HeartMate II, were at an increased risk of infections and had a shorter time to infection (Figure 1) (HeartWare vs. HeartMate II, HR 2.12, P = 0.01). Those with a BMI of ≥35 kg/m(2) were found on average to have a number of infections 0.729 greater than those with a BMI < 35 kg/m(2) (P = 0.01). Prealbumin, A1C, and chronic kidney disease (any stage) were not found to be associated with infection. Staphylococcus aureus (21, 18.26%), Pseudomonas aeruginosa (24, 20.87%), and Staphylococcus epidermidis (22, 19.13%) were the most common organisms identified. CONCLUSION: In an LVAD center where the majority of patients received LVAD as destination therapy, infection rates were similar as those receiving LVAD as a bridge to transplant. Modifiable risk factors for infection are areas for future interventions and prevention efforts. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809134/ http://dx.doi.org/10.1093/ofid/ofz360.1114 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Milgrom, Alexander Collins, Amanda Grubbs, J Aaron Derrick, Caroline Logan, Kristin Edelson, William Branham, Stephany Mardis, Andrew Martin, Jeffrey Weissman, Sharon 1251. Determinants of Infection at a Nontransplanting Cardiothoracic LVAD Program |
title | 1251. Determinants of Infection at a Nontransplanting Cardiothoracic LVAD Program |
title_full | 1251. Determinants of Infection at a Nontransplanting Cardiothoracic LVAD Program |
title_fullStr | 1251. Determinants of Infection at a Nontransplanting Cardiothoracic LVAD Program |
title_full_unstemmed | 1251. Determinants of Infection at a Nontransplanting Cardiothoracic LVAD Program |
title_short | 1251. Determinants of Infection at a Nontransplanting Cardiothoracic LVAD Program |
title_sort | 1251. determinants of infection at a nontransplanting cardiothoracic lvad program |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809134/ http://dx.doi.org/10.1093/ofid/ofz360.1114 |
work_keys_str_mv | AT milgromalexander 1251determinantsofinfectionatanontransplantingcardiothoraciclvadprogram AT collinsamanda 1251determinantsofinfectionatanontransplantingcardiothoraciclvadprogram AT grubbsjaaron 1251determinantsofinfectionatanontransplantingcardiothoraciclvadprogram AT derrickcaroline 1251determinantsofinfectionatanontransplantingcardiothoraciclvadprogram AT logankristin 1251determinantsofinfectionatanontransplantingcardiothoraciclvadprogram AT edelsonwilliam 1251determinantsofinfectionatanontransplantingcardiothoraciclvadprogram AT branhamstephany 1251determinantsofinfectionatanontransplantingcardiothoraciclvadprogram AT mardisandrew 1251determinantsofinfectionatanontransplantingcardiothoraciclvadprogram AT martinjeffrey 1251determinantsofinfectionatanontransplantingcardiothoraciclvadprogram AT weissmansharon 1251determinantsofinfectionatanontransplantingcardiothoraciclvadprogram |